Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab

Oncology Reports

Volumn 28, Issue 1, 2012, Pages 49-54

  Yamazaki, Masanao ^a   Yamashita, Yoshito ^a   Kubo, Naoshi ^a   Yashiro, Masakazu ^a   Ohira, Masaichi ^a   Ako, Eiji ^a   Tanaka, Hiroaki ^a   Muguruma, Kazuya ^a   Sawada, Tetsuji ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cetuximab; ERBB1; ERBB2; Esophageal cancer; Trastuzumab

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURGERY; CARCINOMA CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; FEMALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861565360     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1803     Document Type: Article

References (26)

1. Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med 349: 2241-2252, 2003. (Pubitemid 37485141)
2. Rice TW, Rusch VW, Apperson-Hansen C, et al: Worldwide esophageal cancer collaboration. Dis Esophagus 22: 1-8, 2009.
3. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008. (Pubitemid 351521864)
4. De Vita F, Orditura M, Martinelli E, et al: A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer 104: 427-432, 2011.
5. Lorenzen S, Schuster T, Porschen R, et al: Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 20: 1667-1673, 2009.
6. Citri A and Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516, 2006. (Pubitemid 44036456)
7. Ferguson KM: Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys 37: 353-373, 2008.
8. Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000. (Pubitemid 30428195)
9. Normanno N, Bianco C, De Luca A, Maiello MR and Salomon DS: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10: 1-21, 2003. (Pubitemid 36457237)
10. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001. (Pubitemid 33674041)
11. Citri A, Skaria KB and Yarden Y: The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 284: 54-65, 2003. (Pubitemid 36342255)
12. Normanno N, De Luca A, Bianco C, et al: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16, 2006. (Pubitemid 43199589)
13. Morgan S and Grandis JR: ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res 315: 572-582, 2009.
14. Ekman S, Bergqvist M, Heldin CH and Lennartsson J: Activation of growth factor receptors in esophageal cancer - implications for therapy. Oncologist 12: 1165-1177, 2007. (Pubitemid 350106347)
15. Ekman S, Dreilich M, Lennartsson J, et al: Esophageal cancer: current and emerging therapy modalities. Expert Rev Anticancer Ther 8: 1433-1448, 2008.
16. Kawaguchi Y, Kono K, Mimura K, et al: Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 97: 494-501, 2007. (Pubitemid 47258449)
17. Fiske WH, Threadgill D and Coffey RJ: ERBBs in the gastro-intestinal tract: recent progress and new perspectives. Exp Cell Res 315: 583-601, 2009.
18. Lin CC and Papadopoulos KP: Novel targeted therapies for advanced esophageal cancer. Dis Esophagus 20: 365-371, 2007. (Pubitemid 47323674)
19. Wei Q, Chen L, Sheng L, Nordgren H, Wester K and Carlsson J: EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 31: 493-499, 2007.
20. Pande AU, Iyer RV, Rani A, et al: Epidermal growth factor receptor-directed therapy in esophageal cancer. Oncology 73: 281-289, 2007.
21. Friedlander E, Barok M, Szollosi J and Vereb G: ErbB-directed immunotherapy: antibodies in current practice and promising new agents. Immunol Lett 116: 126-140, 2008.
22. Schmitz KR and Ferguson KM: Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res 315: 659-670, 2009.
23. Friess H, Fukuda A, Tang WH, et al: Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg 23: 1010-1018, 1999. (Pubitemid 29451718)
24. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H and Fujii H: Cetuximab induce antibody-dependent cellular cyto-toxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 120: 781-787, 2007. (Pubitemid 46175397)
25. Mimura K, Kono K, Hanawa M, et al: Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 11: 4898-4904, 2005.
26. Sato S, Kajiyama Y, Sugano M, et al: Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. Int J Radiat Oncol Biol Phys 61: 203-211, 2005. (Pubitemid 40039124)